Elutia Inc
NASDAQ:ELUT

Watchlist Manager
Elutia Inc Logo
Elutia Inc
NASDAQ:ELUT
Watchlist
Price: 4.41 USD -8.88% Market Closed
Market Cap: 152.4m USD
Have any thoughts about
Elutia Inc?
Write Note

Gross Margin
Elutia Inc

42.4%
Current
39%
Average
63.9%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
42.4%
=
Gross Profit
13.4m
/
Revenue
31.5m

Gross Margin Across Competitors

Country Company Market Cap Gross
Margin
US
Elutia Inc
NASDAQ:ELUT
152.1m USD
42%
FR
Pharnext SCA
OTC:PNEXF
6T USD
0%
US
Abbvie Inc
NYSE:ABBV
311.8B USD
67%
US
Amgen Inc
NASDAQ:AMGN
140.7B USD
60%
US
Gilead Sciences Inc
NASDAQ:GILD
115.7B USD
78%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
102.7B USD
86%
US
Epizyme Inc
F:EPE
94.1B EUR
76%
AU
CSL Ltd
ASX:CSL
134.4B AUD
52%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78B USD
87%
US
Seagen Inc
F:SGT
39.3B EUR
75%
NL
argenx SE
XBRU:ARGX
36B EUR
89%
Country US
Market Cap 152.1m USD
Gross Margin
42%
Country FR
Market Cap 6T USD
Gross Margin
0%
Country US
Market Cap 311.8B USD
Gross Margin
67%
Country US
Market Cap 140.7B USD
Gross Margin
60%
Country US
Market Cap 115.7B USD
Gross Margin
78%
Country US
Market Cap 102.7B USD
Gross Margin
86%
Country US
Market Cap 94.1B EUR
Gross Margin
76%
Country AU
Market Cap 134.4B AUD
Gross Margin
52%
Country US
Market Cap 78B USD
Gross Margin
87%
Country US
Market Cap 39.3B EUR
Gross Margin
75%
Country NL
Market Cap 36B EUR
Gross Margin
89%
No Stocks Found

Elutia Inc
Glance View

Market Cap
152.4m USD
Industry
Biotechnology

Aziyo Biologics, Inc. operates as a biotechnology company. The company is headquartered in Silver Spring, Maryland and currently employs 151 full-time employees. The company went IPO on 2020-10-08. The firm is a commercial-stage company that serves two markets with products based on its biomatrix platforms. The company offers a drug-eluting biologic technology: a fusion of natural biologic material and extended antibiotic release, for device implantation and soft tissue reconstruction. Its first product is CanGaroo Envelope, used for the stabilization of implantable cardiac devices, such as pacemakers and defibrillators. Its second product is SimpliDerm Acellular Dermal Matrix, used primarily in breast reconstruction following mastectomy. The company is also engaged in the development of CanGaroo RM, which adds the antibiotics rifampin and minocycline for sustained delivery directly to the surgical site. The Company’s products are used by electrophysiologists and plastic surgeons.

ELUT Intrinsic Value
6.79 USD
Undervaluation 35%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
42.4%
=
Gross Profit
13.4m
/
Revenue
31.5m
What is the Gross Margin of Elutia Inc?

Based on Elutia Inc's most recent financial statements, the company has Gross Margin of 42.4%.